Jiping Wang, MD, PhD

Dr. Jiping Wang is an Associate Professor of Surgery at Harvard Medical School and currently holds the MGB Cancer Endowed Chair at the Mass General Brigham Cancer Institute. His clinical practice focuses on complex gastrointestinal malignancies, including hepatocellular carcinoma (HCC), gastric cancer, pancreatic cancer, and sarcoma, with particular expertise in robotic oncologic surgery, and innovative therapeutic strategies for high-risk and technically challenging cancers.

Dr. Wang received his medical degree from Henan Medical University, graduating in the top 1% of his class. He completed residency training in anesthesiology at the university’s First Affiliated Hospital and subsequently joined the faculty in the Department of Anesthesiology. He later pursued graduate training in biostatistics at the University of Pittsburgh, earning both a Master of Science and a PhD.

From 1998 to 2004, Dr. Wang served as a statistician and senior statistician at the National Surgical Adjuvant Breast and Bowel Project, where he contributed to several landmark oncology trials, including the NSABP P-1 Breast Cancer Prevention Trial and NSABP B-18 neoadjuvant breast cancer trial, working alongside renowned surgical oncologists Bernard Fisher and Norman Wolmark. His early career combined clinical medicine, quantitative science, and clinical trial methodology, forming the foundation for his later translational and surgical oncology research career.

Dr. Wang subsequently completed general surgery residency training at the State University of New York at Buffalo, where he also held an academic appointment in the Department of Biostatistics. He then completed fellowship training in surgical oncology through the combined program of Massachusetts General Hospital, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute from 2009 to 2011. Following fellowship, he joined the faculty at Brigham and Women’s Hospital and Harvard Medical School.

Dr. Wang’s research integrates surgical oncology, clinical trial design, translational science, and quantitative modeling. His work in HCC has focused on early detection strategies, surgical risk prediction, perioperative immunotherapy, and integration of surgery with locoregional and systemic therapies. In gastric and pancreatic cancer, his research has emphasized prognostic modeling, multimodality treatment strategies, perioperative therapy, and optimization of surgical outcomes. He has also been actively involved in the development and clinical implementation of novel technologies in oncologic surgery and image-guided therapy including histotripsy and other ultrasound base devices.

Education & Training

• Fellowship: Massachusetts General Hospital, Surgical Oncology, 2011
• Residency: SUNY at Buffalo, Surgery, 2009
• Residency: Henan Medical University, Anesthesiology, 1996
• Medical Education: Henan Medical University, 1991

Board Certifications

• Surgery (General Surgery), American Board of Surgery

Languages Spoken

• English
• Chinese

Age Group Treated

• Adults